NCT00689507 - A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

January 31, 2013

Study Completion Date

May 31, 2014

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

LY2127399

monoclonal antibody

Trial Locations (6)

Fox Chase Cancer Center, Philadelphia

University of Iowa Hospitals and Clinics, Iowa City

University of Nebraska Medical Center, Omaha

UCLA, Los Angeles

University of Alabama, Birmingham

Dana Farber Cancer Institute, Boston